Company Of The Day: Pfizer

by Trefis Team
+20.12%
Upside
43.15
Market
51.83
Trefis
PFE
Pfizer
Rate   |   votes   |   Share

What? 

Pfizer (NYSE:PFE) and its German partner BioNTech intend to begin clinical trials for an updated version of their Covid-19 vaccine that targets the Delta variant of the Coronavirus.

Why?

The Delta variant apparently more transmissible compared to other strains of the virus. There are also concerns about the efficacy of the current generation of Covid-19 vaccines against the variant.

So What?

Pfizer and BioNtech are already generating windfall profits from their Covid-19 shot. Pfizer projects vaccine sales of $26 billion for this year – a conservative figure, in our view. With shots targeting new virus variants, the companies could keep their Covid vaccine sales going for a few more years.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!